Relationship Between Serum OPN, Try-2, CA199, CA125 And Pancreatic Cancer

Objective:To investigate relationship between Osteopontin(OPN), trypsinogen 2(Try-2), cancer antigen 199(CA199) and cancer antigen 125(CA125) with pancreatic cancer through detecting their serum expression level. Methods: 30 pancreatic cancer patients and 30 healthy persons who had physical check-up in hepticbile surgery department of attached hospital of Guiyang medical college from March, 2013 to October, 2014 were randomly selected as the objective. 30 healthy persons with personnel physical examination was taken as control group and 30 patients with pancreatic cancer were taken as ill group. Enzyme-linked immunosorbent assay(ELISA) method was applied in detecting of serum OPN, Try-2, CA199 and CA125 levels. Value of serum OPN, Try-2, CA199 and CA125 level diagnosing pancreatic cancer and Clinical pathological characteristics of patients were analyzed and Spearman method was applied in analysis of the relationship between serum OPN, Try-2, CA199 and CA125 levels with the clinical pathological characteristics of pancreatic patients. Results:(1)Serum OPN, Try-2, CA199 and CA125 levels of ill group were significantly higher than that of the control group, and difference of serum OPN, Try-2, CA199 and CA125 levels of two groups was statistically significant(t=6.43,35.47,8.73, 5.66, P<0.05).(2)Sensitivity, specificity, misdiagnosis rate, missed diagnosis rate, positive predictive value and negative predictive value of serum OPN level diagnosing pancreatic cancer were 73.33%, 83.33%, 16.67%, 26.67%, 81.84%and 75.76% Respectively(X2=2136.30,988.64,998.64,2136.30,1585.52,1839.45,P<0.05); Sensitivity, specificity, misdiagnosis rate, missed diagnosis rate, positive predictive value and negative predictive value of serum Try-2 level diagnosing pancreatic cancer were 73.33%, 66.67%, 33.33%, 66.67%, 68.75% and 71.43% respectively(X2=2136.30,3005.99,3005.99,2136.30,2725.51, 2376.02, P<0.05); Sensitivity, specificity, misdiagnosis rate, missed diagnosis rate, positive predictive value and negative predictive value of serum CA199 diagnosing pancreatic cancer were 66.67%, 63.33%, 36.33%, 63.33%, 64.52% and 65.52% respectively(X2=3005.99,2473.61,3473.61,3005.99,3304.53,3164.57, P<0.05); Sensitivity, specificity, misdiagnosis rate, missed diagnosis rate, positive predictive value and negative predictive value of serum CA125 diagnosing pancreatic cancer were73.00%, 60.00%, 40.00%, 60.00%, 63.64% and 66.67% respectively( X2=2560.84,3961.66,3961.66,2560.84,3429.30,3005.99,P<0.05); And sensitivity, specificity, misdiagnosis rate, missed diagnosis rate, positive predictive value and negative predictive value of Try-2, CA199 and CA125 levels unitedly diagnosing pancreatic cancer were 96.67%, 96.67%, 3.33%, 96.67%, 96.67% and 96.67% respectively.(3) When the clinical stage of pancreatic patients was higher, Serum OPN,Try-2, CA199 and CA125 level of pancreatic patients were also higher(clinical stage I: 35.65±8.95 ng/ml,8.14±1.55 ng/ml,185.48±23.26 k U/L, 36.78±2.52 k U/L; clinical stage II: 49.72±7.25 ng/ml, 10.18±2.06ng/ml, 143.62±62.92 k U/L,48.92±3.65 k U/L; clinical stage III: 59.95±9.78ng/ml, 14.42±3.32ng/ml,288.45±71.18 k U/L, 60.75±8.52 k U/L; clinical stage IV: 70.42±6.58) ng/ml,18.95±4.18ng/ml,326.58±80.85 k U/L,71.45±10.61 k U/L; comparative differences between groups were statistically significant, P<0.05); The above indicators of pancreatic patients with lymph node metastasis were also significantly higher than that of patients without lymph node metastasis(patients with lymph node metastasis: 68.44±11.95ng/ml,17.96±4.21ng/ml,295.76±81.52 k U/L,69.15±9.78 k U/L; patients without lymph node metastasis:41.48±9.52ng/ml,10.44±3.62ng/ml,195.85±43.65 k U/L, 35.46±2.25 k U/L, t=6.54, 5.22, 83.88, 11.66, P<0.05). Spearman method analyzing results showed that serum OPN, Try-2, CA199 and CA125 level of pancreatic cancer patients were positively correlated with its clinical stage(r=0.792, 0.765,0.743,0.755,P<0.05) and lymph node metastasis(r=0.765,0.778,0.751,0.749,P<0.05). Conclusion: ⑴Serum OPN, Try-2, CA199 and CA125 level in patients with pancreatic cancer are significantly higher. ⑵Serum OPN, Try-2, CA199 and CA125 level are valuable in diagnosing pancreatic cancer and thecomination of the obove 4 items diagnosing pancreatic cancer has higher value for it can gain high sensitivity and specificity and low misdiagnosis rate and missed diagnosis rate. ⑶Serum OPN, Try-2, CA199 and CA125 levels are associated with the clinical pathological features of pancreatic cancer, which means that the 3 indicators are of great importance in measuring disease degree of pancreatic cancer.